How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers? Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy? How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?

Fostering Thought leadership in Healthcare

Biocon Bats for Affordable Insulin and Ozempic

🩺 Insulin, Innovation, and Independence: How Biocon, Civica, and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Marketing

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Policies/Sales

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Strategy

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Incentives in Healthcare: The Quiet Force Shaping Outcomes

In 2017, economist Richard Thaler won the Nobel Prize...

Bring Your Own Learning

Articles by K. Hariram, Vivek Hattangadi, DigiPharmaX, Satya Mahesh, Ajesh Shah and Phanish Chandra

Pharma – Physician Interactions in the Digital Era

Indian Pharma companies will have to create hybrid employees, who can be designated as the Digital Task Force (DTF). Just as STFs were created to create a better perception and improve engagement with specialist doctors, DTF can rebuild relationships with doctors on a new premise of helping them to gain digital advantage to better manage their practice and patients.

Key Challenges Facing Indian Pharma

With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience. The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.